viernes, 6 de noviembre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 5, 2025

Bank of America Shares Climb 23.1% YTD: Is It Too Late to Buy?

View original at finance.yahoo.com
Bank of America Shares Climb 23.1% YTD: Is It Too Late to Buy? Shares of Bank of America BAC, the second-largest U.S. bank, are poised for another year of double-digit gains, building on its strong 30.5% rally in 2024…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Bank of America targets mid-single-digit CAGR in IB fees and a 50 to 100-bp market share gain over the medium term

    80% confidence

  • Zacks Consensus Estimate for 2026 earnings per share is $4.35

    80% confidence

  • JPMorgan anticipates 2025 NII to be $95.8 billion, up more than 3% year over year

    80% confidence

  • Bank of America targets a 55-59% efficiency ratio

    80% confidence

  • Bank of America projects a 5-7% year-over-year increase in NII for 2026, after similar growth this year

    80% confidence

  • Zacks Consensus Estimate for 2025 earnings per share is $3.80

    80% confidence

  • Citigroup expects NII (excluding Markets) to grow 5.5% for 2025

    80% confidence

  • Bank of America carries a Zacks Rank #2 (Buy)

    80% confidence

  • Bank of America aims to achieve earnings growth of almost 12% in the medium term

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,996
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,996 hechos verificados con la fuente5,552 documentos fuente archivados
Consulta estos datos → isubstrate.com
Bank of America Shares Climb 23.1% YTD: Is It Too Late to Buy? — Source | Via News | es.VIA.NEWS